788 results about "Therapeutic strategy" patented technology

The invention discloses an inflammation-targeting bionic extracellular vesicle as well as a preparation method and application thereof, and particularly relates to the field of medicines. According to the invention, a new generation of aminoglycoside antibiotic teicoplanin (Teic), which is high in albumin binding rate and weak in intracellular antibacterial effect, is loaded on neutrophil-derived extracellular vesicles (NEV) with natural drug carrying capacity and inflammatory response chemotactic capacity to prepare the drug-loaded vesicles (Teic-NEV), wherein the new generation of aminoglycoside antibiotic teicoplanin (Teic) is used for loading the neutrophil-derived extracellular vesicles (NEV). The drug-loaded extracellular vesicle Teic-NEV can be used for targeted therapy of cells and tissues infected by MRSA (Methicillin-Resistant Staphylococcus Aureus). In vitro, the Teic (at) NEV can be used for destroying MRSA mature biological membranes and killing intracellular MRSA. According to the invention, the in-vivo and in-vitro biological safety of the TeicatNEV is evaluated. Therefore, the invention provides a certain theoretical basis for the application of NEV-based drug delivery in the field of intracellular bacteria treatment, and also provides a new treatment strategy for in-vivo targeted treatment.

The invention discloses bifidobacterium animalis subsp. Lactis, a preparation and application of the bifidobacterium animalis subsp. Lactis in regulation of depression and intestinal flora. Belongs to the technical field of probiotic preparation. According to the application, seven strains of bacteria are separated from excrement of infants, the seven strains of bacteria comprise bifidobacterium breve, bifidobacterium animalis and bifidobacterium longum through identification, the anti-depression capacity of the seven strains of bacteria is evaluated through in-vitro experiments, a potential antidepressant bifidobacterium animalis subsp. Lactis BD1 is screened out, and further experiments prove that the antidepressant bifidobacterium animalis subsp. Lactis BD1 has the advantages that the antidepressant bifidobacterium animalis subsp. Lactis BD1 can be used for preparing the antidepressant bifidobacterium animalis subsp. Lactis BD1; the strain has the effects of improving depressive mood, intestinal bacteria unbalance and insufficient serotonin secretion in the brain caused by chronic bound stress (CRS), and compared with bifidobacterium animalis subsp. Lactis in the prior art, the strain achieves the anti-depression effect from multiple aspects, also has the effect of adjusting intestinal flora imbalance, and has the advantages of being safe and reliable. And a new treatment strategy is provided for depression and intestinal flora imbalance.

The invention belongs to the technical field of genetic engineering and biological medicine, and particularly discloses a cascade response type nano-particle with a microenvironment remodeling function and a preparation method and application of the cascade response type nano-particle. The nanoparticle provided by the invention adopts a bionic hybrid membrane engineering strategy: an inner core is formed by loading an exosome inhibitor on a nano material, and the surface is covalently coupled with M2 type macrophage specific targeting peptide; the outer layer coats a macrophage membrane and active oxygen response type liposome composite membrane layer through a co-extrusion technology, and is loaded with a TLR agonist. Animal experiments show that after being injected through caudal vein, the nano-particles are enriched at a tumor site in a targeted manner through homing receptors such as membrane surface integrin alpha4beta1 and the like, and outer membrane cracking is triggered in a high-ROS tumor microenvironment, so that space-time controlled release of a TLR agonist and targeted phagocytosis of an exosome inhibitor by macrophages guided by a targeted peptide are realized. The anti-tumor synergistic effect is achieved through multiple regulation and control mechanisms, and an effective treatment strategy is provided for tumor immunotherapy.

The invention belongs to the field of biological medicines, and discloses an application of Akkermansia muciniphila or an extracellular vesicle of the Akkermansia muciniphila in preparation of a medicine for alleviating the ischemic necrosis of the alcoholic femoral head. Based on the pathogenesis characteristics of the AIONFH, the Akk bacteria and the extracellular vesicles thereof are used for treating the AIONFH for the first time, the molecular mechanism of the Akk bacteria and the extracellular vesicles thereof for regulating and controlling the intestinal tract-skeleton axis function, inhibiting bone cell apoptosis and improving the bone trabecula microstructure is deeply researched, the anti-pressure ability of bone tissue is improved, and the research blank in the field is filled. Compared with a traditional treatment method, the osteonecrosis pathological change is improved through a single way, and a novel multi-target treatment strategy is provided from multiple aspects of regulating inflammatory response, recovering bone metabolism balance, promoting intraosseous blood supply and the like.

The invention discloses a preparation method and application of a BG (at) ZIF-8 organic-inorganic nanofiber membrane, and belongs to the field of biomedical composite materials. The method comprises the following steps: preparing BG through high-temperature calcination, wrapping the BG in ZIF-8 by using a wrapping technology to form BG-coated ZIF-8, and then carrying out microfluidic electrostatic spinning on the BG-coated ZIF-8, PCL and PVA to obtain a nanofiber membrane containing Zn < 2 + >, Ca < 2 + > and Si < 4 + > for diabetes wound healing. The ions can be slowly released to promote growth factor expression and revascularization. Experiments prove that BG (at) ZIF-8 / PCL-PVA can inhibit diabetes mellitus wound inflammation and accelerate healing. The composite fiber membrane using the micro-fluidic electrostatic spinning technology provides a new view angle for wound healing of diabetes, and is a potential efficient treatment strategy.

The invention discloses a sesterterpenoid compound, a preparation method thereof and application of the sesterterpenoid compound in preparation of a medicine for treating psoriasis, and belongs to the technical field of biological medicine. Comprising a compound 1-4, and the structural formula of the compound 1-4 is as follows: # imgabs0. A new molecular template is provided for developing a new psoriasis treatment medicine, and a new thought is provided for further developing a novel treatment strategy with an immunomodulatory effect.

The invention belongs to the technical field of biological medicines, and particularly relates to an iron-based nano material, a preparation method and application of the iron-based nano material in preparation of medicines for treating breast cancer. The iron-based nano material is formed by loading a ferroptosis inducer on a nano carrier; the nano carrier is an iron-based metal organic framework material Fe-MOF (Metal Organic Framework). A product FEH for treating breast cancer is obtained based on coupling of the iron-based nano-material provided by the invention with a targeted drug such as trastuzumab. The FEH provides a new method for developing a nano platform with an antibody function, and realizes a treatment strategy of trastuzumab and ferroptosis combined anti-tumor. As a safe and effective tumor treatment strategy, the EFH has huge clinical transformation potential.

The invention relates to the technical field of genetic engineering, in particular to a long-chain RNALnc012227 for inhibiting transmission of salmonella enteritidis ovary and application of the long-chain RNALnc012227 in prevention and control of salmonella enteritidis infection. The invention relates to a long-chain RNA (Ribonucleic Acid) Lnc012227 for inhibiting transmission of salmonella enteritidis ovary. The Lnc012227 provided by the invention can be used for indirectly regulating the expression of MAP3K8, activating NF-kappa B and MAPK signal channels and enhancing the inflammatory response of a host, so that S.Enteridis infection is controlled. The discovery not only provides a new understanding of molecular level for understanding the infection mechanism of salmonella in the duck body, but also provides a potential target spot for developing a new treatment strategy, and is helpful for reducing egg-laying duck ovarian infection and duck egg pollution caused by salmonella.

The invention provides a follow-up visit consultation system for chronic pain patients, and relates to the technical field of intelligent medical treatment, and the system comprises a data collection unit which is used for obtaining subjective pain description data, real-time physiological monitoring data and historical diagnosis and treatment data of a patient; the prediction analysis unit is used for performing pain deterioration risk prediction based on the multi-source data and an artificial intelligence model, and outputting a prediction result containing a risk level and individualized pathological features; and the dynamic intervention unit is used for generating dynamic treatment suggestions according to the prediction result, pushing the dynamic treatment suggestions to the doctor and the patient, and receiving execution feedback data of the patient so as to perform closed-loop optimization on the treatment strategy. According to the technical scheme, the subjective pain description, the real-time physiological monitoring data and the historical diagnosis and treatment records of the patient are obtained at the same time, the integrity of the data is improved through the comprehensive collection mode of multi-source data, the accuracy and timeliness of information are ensured, and the problems of subjective deviation and inaccuracy caused by the fact that follow-up visit depends on memory of the patient are solved.

The present invention relates to a use of THBS1 as a novel combination drug target that can overcome drug resistance of a targeted anticancer agent. A THBS1 inhibitor according to the present invention inhibits the drug resistance of a target anticancer agent and thus increases an anticancer effect when administered in combination with a target anticancer agent. Accordingly, the present invention can overcome resistance to a targeted anticancer agent and increase a treatment success rate of anticancer drugs for cancer patients, thereby suggesting new possibilities for treatment strategies using targeted anticancer drugs and contributing to the realization of precision medicine.

The invention discloses an application of a small molecule compound SFII in preparation of drugs for resisting pyroptosis and GSDMD inhibitors with pyroptosis resisting activity. The small molecule compound Scutellaria flavone II (SII) extracted from Scutellaria baicalensis roots plays an important role in preparation of drugs for inhibiting pyroptosis inflammation so as to prevent or treat atherosclerosis. Experiments prove that the active pharmaceutical ingredient SFII has a definite effect on promoting atherosclerosis by virtue of Gasdermin D and GSDMD mediated macrophage pyroptosis, is convenient to obtain, can be used for preparing drugs for inhibiting GSDMD protein activity to resist pyroptosis and exerting an anti-inflammatory effect so as to prevent or treat atherosclerosis, and has a remarkable effect. The small molecule compound SFII provides a new treatment strategy for atherosclerosis, and has a wide application prospect.

The invention discloses application of a stem cell exosome in treating depression-like behaviors caused by high-altitude hypoxia, and belongs to the technical field of biomedicine. The stem cell exosome is an exosome derived from human umbilical cord mesenchymal stem cells, and is used for drugs for preventing and / or treating depression-like behaviors caused by high-altitude hypoxia. The exosome can effectively improve depression-like core behavior symptoms caused by high-altitude hypoxia by regulating a brain-intestinal axis; the method starts from remodeling intestinal flora so as to influence the intracerebral metabolite spectrum, and finally plays a role in neuroprotection by regulating and controlling a 5-HT6 / cAMP-PKA key signal channel. In addition, the combination of the hUC-MSC-exo and probiotics shows synergistic interaction potential, and a potential treatment strategy which is novel in mechanism, remarkable in effect and high in safety is provided for the field.

The invention belongs to the technical field of biological medicine, and particularly relates to application of hUC-MSCs combined with Met in preparation of anti-diabetic drugs. The diabetes mellitus is particularly type 2 diabetes mellitus. Through construction of a T2DM rat model, paraffin tissue section detection, serum ELISA, cell experiments and the like, researches prove that T2DM can be effectively treated by HUC-MSCs combined with Met treatment, including reduction of body blood sugar and recovery of blood sugar regulation ability; liver injury caused by T2DM is relieved and repaired; the glycolipid metabolism of the liver of the T2DM rat is improved; the immune inflammation disorder caused by T2DM is relieved; and the apoptosis level of liver cells is improved. And compared with a single hUC-MSCs or Met treatment mode, the combined treatment mode has a better treatment effect. The invention provides a theoretical basis and a new treatment strategy for treatment of T2DM.

The invention relates to the technical field of biomedicine, in particular to a liver cancer molecular subtype typing and prognosis model construction method based on glycometabolism and lactic acid metabolism related genes and application thereof. According to the invention, the typing and prognosis model of liver cancer subtypes is constructed for the first time on the basis of a coordinated regulation network of a glycometabolism gene and a lactic acid metabolism gene, the constructed liver cancer subtype subtypes comprise Cluster1 and Cluster2, and the total survival rates of different subtypes have significant difference; the clinical characteristics T.stage and TNM.stage of different subtypes are obviously different from each other; 12 kinds of immune cells have significant differences among different subtypes; iPS immune scores of different subtypes are significantly different; the TIDE scores of different subtypes have significant score differences; the genes with the highest mutation frequency in different subtypes comprise TP53, CTNNB1 and TTN. CLM scores of the prognosis model constructed on the basis of the collaborative regulation network of the glycometabolism genes and the lactic acid metabolism genes have no significant difference in different patient states; the 17 immune cells have significant differences between high and low risk groups. And a new way is provided for individualized treatment strategy formulation and survival outcome improvement of HCC.

The invention discloses a pharmaceutical composition for treating hashimoto thyroiditis, and belongs to the technical field of traditional Chinese medicines. According to the pharmaceutical composition, astragalus membranaceus and codonopsis pilosula are used as monarch drugs to tonify qi, raise yang, tonify qi and strengthen body resistance; radix bupleuri, rhizoma cyperi and radix curcumae are used as ministerial drugs for soothing liver-qi stagnation, expelling evil, soothing liver-qi, regulating qi and harmonizing blood; humifuse euphorbia herb, lucid ganoderma and oldenlandia diffusa are used as adjuvant drugs for clearing away heat and toxic materials, reinforcing qi, nourishing blood and tranquilizing; the whole formula has the effects of tonifying qi, soothing the liver and clearing heat together. All the medicines are combined to effectively improve the symptoms of patients with hashimoto thyroiditis and reduce the thyroid autoantibody level. In addition, the pharmaceutical composition is good in safety, and a traditional Chinese and western medicine combined treatment strategy for hashimoto thyroiditis can be further popularized in the future.

The invention discloses an extraction method of safflower leaf exosome-like nano-vesicles and application of the safflower leaf exosome-like nano-vesicles in preparation of drugs for preventing and treating adriamycin-induced cardiotoxicity, fresh safflower leaves are taken and cleaned, a PBS solution is added for crushing and filtering, filtrate is collected and continuously centrifuged, supernate is taken and subjected to ultracentrifugation, precipitates are collected after centrifugation, and the safflower leaf exosome-like nano-vesicles are obtained; and filtering and sterilizing by using a filter membrane to obtain the safflower leaf exosome-like nano-vesicles. The carthamus tinctorius leaf exosome-like nano-vesicles can significantly improve the heart function of doxorubicin-induced cardiotoxic mice; myocardial injury induced by doxorubicin can be repaired, and myocardial fibrosis induced by doxorubicin can be inhibited; the content of a myocardial injury marker lactic dehydrogenase in body serum can be reduced, a new treatment strategy is provided for preventing and treating adriamycin-induced cardiotoxic diseases, and the application prospect is good.

The invention belongs to the technical field of biological medicines, and particularly discloses application of ORM1 protein or VIM knockout adenovirus in preparation of a medicine for treating temporomandibular joint osteoarthritis (TMJOA). The invention proves that the expression of ORM1 is reduced in synovial fluid of a TMJOA patient and a unilateral anterior tooth reverse inhale model rat, and the degradation of cartilage matrix of the UAC rat can be remarkably inhibited and the progress of TMJOA can be relieved by locally injecting ORM1 protein. On the mechanism level, ORM1 is combined with waveform protein VIM to inhibit an MAPK channel, so that expression of MMP13 and MMP3 is reduced, cartilage matrix degradation is reduced, and cartilage steady state is maintained. In addition, the invention also finds that after the VIM of the rat is knocked out by using the adeno-associated virus, the progress of TMJOA, including cartilage degeneration and subchondral bone destruction, is also obviously improved. Therefore, the invention provides a new therapeutic target and a new therapeutic strategy for the TMJOA.

The invention relates to the technical field of biological medicine, in particular to an ulcerative colitis disease clearance evaluation molecular marker and application thereof. By detecting the expression level of the HMGCS2 gene in a sample, the ulcerative colitis disease clearance state and disease activity period can be evaluated, and the method is used for curative effect monitoring, recurrence prediction and individualized treatment strategy formulation of ulcerative colitis and has important clinical application value and market prospect.

The invention belongs to the technical field of biological medicines, and particularly relates to application of ganoderic acid A in preparation of a medicine for preventing and / or treating biliary atresia. The new application of ganoderic acid A in preparation of drugs for preventing and / or treating biliary atresia is found for the first time. The method comprises the following steps: within 24 hours after a BALB / c newborn mouse is born, inducing the formation of BA by intraperitoneal injection of RRV, and from the second day after intraperitoneal injection of RRV, carrying out intraperitoneal injection of Ganoderic Acid A on the mouse every day until the twelfth day, it can be observed that the survival time of BA mice treated by the Ganoderma Acid A is prolonged, the weight loss is obviously improved, the jaundice symptom is relieved, the liver function index is obviously improved, the infiltration number of inflammatory cells around the intrahepatic bile duct is obviously reduced, and the liver bile duct injury is relieved. The invention provides a new potential target and a treatment strategy for treatment of BA, and has potential clinical treatment significance.

The invention relates to the technical field of biomedicine, in particular to siRNA (small interfering ribonucleic acid) for interfering Tc11a gene expression, a core-shell type nano particle as well as a preparation method and application of the core-shell type nano particle. The invention relates to a method for treating type I diabetes mellitus by using core-shell nanoparticles (siTc11a NPs) of a targeted mouse Tc11a gene on an NOD model mouse, and provides a preparation method of the nanoparticles. The preparation method comprises the following steps: mixing siRNA (small interfering ribonucleic acid) interfering with a Tc11a gene with cationic liposome G0-C14 to obtain a complex; mixing the complex with a polylactic acid-glycolic acid copolymer to obtain a core substance; and mixing the core substance with the lipid polymer to obtain the core-shell nanoparticles. The invention provides a treatment strategy for treating the type I diabetes mellitus through targeted Tcl1a gene regulation and control.

The invention discloses an endogenous small molecule metabolite for treating obesity and related metabolic diseases thereof, and belongs to the field of biological medicine. Specifically, the invention relates to application of hippuric acid in preparation of anti-obesity drugs. The invention discloses a technical scheme for treating obesity and related metabolic disorders by hippuric acid, and overcomes the defects of single curative effect, larger side effect or unclear action mechanism and the like in the prior art through the advantages of targeted improvement of liver fatty degeneration, improvement of insulin sensitivity, higher potential safety, provision of a new treatment strategy and the like. The method has remarkable technical progress and clinical application value.

The invention discloses application of swertiflavin in preparation of a medicine for treating infectious pneumonia caused by methicillin-resistant staphylococcus aureus, and relates to the technical field of medicine. It is found for the first time that swertiflavin can significantly reduce the toxicity of staphylococcus aureus by inhibiting the activity of ClpP protein in MRSA. In addition, the swertiflavin shows a remarkable protection effect in the treatment of the MRSA infectious pneumonia. Specifically, the swertiflavin not only can relieve the injury degree of lung tissues, but also can reduce infiltration and aggregation of inflammatory cells in the lung. The discovery shows that the swertiflavin has potential application value in the field of anti-infection treatment. The invention provides a novel treatment strategy, namely, swertiflavin is used as an active ingredient for preparing the medicine for treating the staphylococcus aureus infectious pneumonia.

The invention discloses an application of a pyroptosis inhibitor in preparation of a product for treating biliary atresia, the pyroptosis inhibitor 2-bromohexadecanoic acid has a certain treatment effect on biliary atresia mice, can significantly prolong the survival time of the mice, improve jaundice, improve the liver function of the mice, reduce the infiltration quantity of inflammatory cells around intrahepatic bile ducts, and can be used for treating the biliary atresia. A new potential target and a treatment strategy are provided for treatment of biliary atresia.

The invention belongs to the technical field of biological medicines, and particularly relates to a ferrozirconium bimetallic nano-material, a preparation method and application of the ferrozirconium bimetallic nano-material in preparation of medicines for treating breast cancer. The ferrozirconium bimetallic nano material is formed by loading a CDK4 / 6 inhibitor on a nano carrier; wherein the nano carrier is an organic framework material Zr-Fe MOF containing double metals of Zr and Fe, and the CDK4 / 6 inhibitor is preferably ribociclib. A product ZFRH for treating breast cancer is obtained based on coupling of the ferrozirconium bimetallic nano-material provided by the invention with a targeted drug such as trastuzumab. The ZFRH provides a new method for developing a nano platform with an antibody function, and realizes a treatment strategy of combined anti-tumor of trastuzumab and a CDK4 / 6 inhibitor. As a safe and effective tumor treatment strategy, the ZFRH has huge clinical transformation potential.

The invention relates to the field of biological medicine, and discloses application of LPC, PC and AA in children sepsis diagnosis and prognosis product development. According to the invention, a high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS / MS) technology is used, plasma samples of a child sepsis patient and a healthy control group are compared, the relationship between lipidome change and pSOFA score is analyzed, and specific lipid molecules closely related to disease severity and prognosis are identified. According to the invention, the following lipid molecules are highlighted as key biomarkers: lysophosphatidylcholine (LPC), phosphatidylcholine (PC) and arachidonic acid (AA). The change of the lipid molecules is closely related to the physiological state of a child sepsis patient, and the lipid molecules can be used for early diagnosis and evaluation of the state of the child sepsis, so that the treatment effect and the accuracy of prognosis evaluation are improved, and a new treatment strategy and a new management method are provided for clinic.

The invention belongs to the technical field of cell bionic nano-drugs, and particularly discloses a cell bionic nano-particle as well as a construction method and application thereof. And performing simple ultrasonic fusion on the target cell membrane and the hydrophobic nano-core to obtain the cell bionic nano-particles. The bionic nano-cell can effectively inherit and simulate functional protein on the surface of a source cell membrane, systematically replace functions of the source cell in physiological and pathological processes, such as inflammatory factor adsorption, migration factor adsorption and the like, interfere and inhibit the disease process from the cellular mechanism, regulate and control cell composition and immune microenvironment of a focus part, and improve the immune function of the source cell membrane. The medicine does not need to be additionally carried. Aiming at the related pathogenesis of immune tolerance deficiency, the invention innovatively provides a therapeutic strategy for constructing immune tolerance. The homology and inherent immunosuppressive ability of tumor cells to the focus part of the autoimmune disease are reversely used, immune tolerance of the focus part based on immune checkpoints is reconstructed, meanwhile, target cells are replaced to adsorb autoimmune antibodies, and the immune response level is reduced.

The invention discloses an application of intestinal bacteria in an ulcerative colitis prediction technology, and belongs to the technical field of biology, and the intestinal bacteria are Alistipes finegoldii; the method comprises the following steps: detecting the relative abundance of Alistipes finegii in an excrement sample of a patient, and using the low relative abundance of Alistipes finegii to predict the disease activity of ulcerative colitis; according to the application disclosed by the invention, not only is the association between the Alistipes finegili and the UC disease activity verified, but also the potential action mechanism of the Alistipes finegili is further explored. By means of 16s amplicon sequencing and transcriptomics combined analysis, it is found that the Alistipes finegili plays an anti-inflammatory role through an Hsp90 / AMPK / ACC signal channel, and the intestinal barrier function is maintained. The invention verifies that a new view angle is provided for the effect of the Alistipes finegili in the UC pathogenesis, and provides a theoretical basis for developing a treatment strategy based on the strain.

The invention discloses a method for identifying early-stage diabetic patients based on physiological and biochemical indexes. The method comprises the following steps: collecting data; analyzing and preprocessing data; a BP neural network model is adopted, and the model comprises an input layer, six hidden layers and an output layer; model training: dividing the source data into a training set and a test set according to the ratio of 7: 3 for model training, the training round epoch is 70, the batch size is 16, and in the training process, 10% of the training data is used as a verification set for evaluating the performance; and evaluating a result. By comprehensively considering the multi-dimensional clinical data of the patient, the classification model capable of accurately identifying the risk of the early diabetes mellitus of the individual is developed, and the accuracy and reliability of early diabetes mellitus identification are improved; and a doctor can be assisted to formulate personalized prevention and treatment strategies through the identification result of the model.

The invention belongs to the technical field of biological medicines, and particularly relates to placenta targeting peptide plCSA-BP modified tetrahedral framework nucleic acid as well as a preparation method and application thereof. The placenta targeting peptide plCSA-BP is creatively combined with tFNAs to form a tFNAs / plCSA-BP compound, the compound has excellent placenta targeting property and can effectively improve the function of placenta trophoblasts, so that the treatment effect of preeclampsia is remarkably improved, a new treatment strategy is provided for the placenta diseases in the gestation period, and the placenta targeting peptide plCSA-BP has a good application prospect. The application prospect of the nano material in placental disease treatment is expanded.

Methods for testing the effects of therapeutic compound candidates on a phenotypic organoid model is provided. Such a method includes steps of generating the phenotypic organoid model on a high throughput screening platform, treating the organoid with a therapeutic compound candidate, and testing one or more effects resulting from treatment with each of the therapeutic compound candidates. The testing method that has led to identification of a method for treating or preventing cysts is provided. That method may include contacting a population of cells with an inotrope, wherein the inotrope prevents cyst formation, shrinks existing cysts, or both. That method may be used to treat cystogenic diseases or conditions such as Polycystic Kidney Disease (PKD).